Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
154.68
-3.26 (-2.06%)
At close: Mar 28, 2025, 4:00 PM
149.74
-4.94 (-3.19%)
Pre-market: Mar 31, 2025, 8:45 AM EDT
Ascendis Pharma Revenue
In the year 2024, Ascendis Pharma had annual revenue of 363.64M EUR with 36.34% growth. Ascendis Pharma had revenue of 173.92M in the quarter ending December 31, 2024, with 26.30% growth.
Revenue (ttm)
363.64M EUR
Revenue Growth
+36.34%
P/S Ratio
23.79
Revenue / Employee
357,562 EUR
Employees
1,017
Market Cap
9.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ASND News
- 4 weeks ago - Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? - Benzinga
- 6 weeks ago - Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - GlobeNewsWire
- 2 months ago - Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade) - Seeking Alpha
- 2 months ago - Ascendis Pharma: Danish Blockbuster Hunter - Seeking Alpha